Patterns of C-reactive protein release following allogeneic stem cell transplantation are correlated with leukemic relapse

Bone Marrow Transplantation

Volumn 37, Issue 5, 2006, Pages 493-498

  Min, C K ^a,b   Kim, S Y ^a   Eom, K S ^a   Kim, Y J ^a   Kim, H J ^a   Lee, S ^a   Kim, D W ^a   Lee, J W ^a   Min, W S ^a   Kim, C C ^a  

^a The Catholic University of Korea   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

C reactive protein; Leukemic relapse; Stem cell transplantation

Indexed keywords

ANTIBIOTIC AGENT; C REACTIVE PROTEIN; CYCLOSPORIN; CYTARABINE; FLUDARABINE; HEPARIN; MELPHALAN; METHOTREXATE; TSUKUBAENOLIDE;

ABDOMINAL RADIOTHERAPY; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CORRELATION ANALYSIS; CORRELATION FUNCTION; CYTOMEGALOVIRUS INFECTION; FEMALE; FEVER; GRAFT VERSUS LEUKEMIA EFFECT; HEMORRHAGIC CYSTITIS; HEPATITIS B; HIGH RISK PATIENT; HUMAN; LEUKEMIA RELAPSE; LIVER VENOOCCLUSIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROTEIN SECRETION; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; T LYMPHOCYTE ACTIVATION;

ADOLESCENT; ADULT; C-REACTIVE PROTEIN; FEMALE; GRAFT VS HOST DISEASE; GRAFT VS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROBABILITY; PROGNOSIS; RECURRENCE; RETROSPECTIVE STUDIES; TRANSPLANTATION, HOMOLOGOUS;

EID: 33645294053     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705276     Document Type: Article

References (33)

1. Barrett AJ. Mechanisms of the graft-versus-leukemia reaction. Stem Cells 1997; 15: 248-258.
2. Uberti JP, Ayash L, Braun T, Reynolds C, Silver S, Ratanatharathorn V. Tacrolimus as monotherapy or combined with minidose methotrexate for graft-versus-host disease prophylaxis after allogeneic peripheral blood stem cell transplantation: Long-term outcomes. Bone Marrow Transplant 2004; 34: 425-431.
3. Kumar L. Leukemia: Management of relapse after allogeneic bone marrow transplantation. J Clin Oncol 1994; 12: 1710-1717.
4. Schultz DR, Arnold PI. Properties of four acute phase proteins: C-reactive protein, serum amyloid A protein, alpha 1-acid glycoprotein and fibrinogen. Sem Arthritis Rheum 1990; 20: 129-147.
5. Cooke KR, Okliewicz K, Erickson N, Ferrara JL. The role of endotoxin and the innate immune response in the pathophysiology of acute graft versus host disease. J Endotoxin Res 2002; 8: 441-448.
6. Schots R, Van Riet I, Ben Othman T, Trullemans F, De Waele M, Van Camp B et al. An early increase in serum levels of C-reactive protein is an independent risk factor for the occurrence of major complications and 100-day transplant-related mortality after allogeneic bone marrow transplantation. Bone Marrow Transplant 2002; 30: 441-446.
7. Schots R, Kaufman L, Van Riet I, Ben Othman T, De Waele M, Van Camp B et al. Proinflammatory cytokines and their role in the development of major transplant-related complications in the early phase after allogeneic bone marrow transplantation. Leukemia 2003; 17: 1150-1156.
8. Chalandon Y, Roosnek E, Mermillod B, Newton A, Ozsahin H, Wacker P et al. Prevention of veno-occlusive disease with defibrotide after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2004; 10: 347-354.
9. Van Rhee F, Lin F, Cullis O, Spencer A, Cross NC, Chase A et al. Relapse of chronic myeloid leukemia after allogeneic bone marrow transplantation: The case for giving donor leukocyte transfusions before the onset of hematologic relapse. Blood 1994; 83: 3377-3383.
10. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974; 18: 295-304.
11. Weisdorf DJ, Snover DC, Haake R, Miller WJ, McGlave PB, Blazar B et al. Acute upper gastrointestinal graft-versus-host disease: Clinical significance and response to immunosuppressive therapy. Blood 1990; 76: 624-629.
12. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825-828.
13. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204-207.
14. Atkinson K, Horowitz MM, Gale RP, Lee MB, Rimm AA, Bortin MM. Consensus among bone marrow transplanters for diagnosis, grading, and treatment of chronic graft-versus-host disease. Bone Marrow Transplant 1989; 4: 247-254.
15. Mehta J, Powles R, Kulkarni S, Treleaven J, Singhal S. Induction of graft-versus-host disease as immunotherapy of leukemia relapsing after allogeneic transplantation: Single-center experience of 32 adults patients. Bone Marrow Transplant 1997; 20: 129-135.
16. McDonald GB, Sharma P, Matthews DE, Shulman HM, Thomas ED. Venocclusive disease of the liver after bone marrow transplantation: Diagnosis, incidence, and predisposing factors. Hepatology 1984; 4: 116-122.
17. Choi SM, Lee DG, Choi JH, Yoo JH, Kim YJ, Park SH et al. Risk-adapted preemptive therapy for cytomegalovirus disease after allogeneic stem cell transplantation: A single-center experience in Korea. Int J Hematol 2005; 81: 69-74.
18. Riddell SR, Berger C, Murata M, Randolph S, Warren EH. The graft versus leukemia response after allogeneic hematopoietic stem cell transplantation. Blood Rev 2003; 17: 153-162.
19. Xun CQ, Thompson JS, Jennings CD, Brown SA, Widmer MB. Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2-incompatible transplanted SCID mice. Blood 1994; 83: 2360-2367.
20. Cavender DE, Haskard DO, Joseph B, Ziff M. Interleukin 1 increases the binding of human B and T lymphocytes to endothelial cell monolayers. J Immunol 1986; 136: 203-207.
21. Leeuwenberg JF, Van Damme J, Meager T, Jeunhomme TM, Buurman WA. Effects of tumor necrosis factor on the interferon-gamma-induced major histocompatibility complex class II antigen expression by human endothelial cells. Eur J Immunol 1988; 18: 1469-1472.
22. Pober JS, Collins T, Gimbrone Jr MA, Libby P, Reiss CS. Inducible expression of class II major histocompatibility complex antigens and the immunogenicity of vascular endothelium. Transplantation 1986; 41: 141-146.
23. Thornhill MH, Wellicome SM, Mahiouz DL, Lanchbury JS, Kyan-Aung U, Haskard DO. Tumor necrosis factor combines with IL-4 or IFN-gamma to selectively enhance endothelial cell adhesiveness for T cells. The contribution of vascular cell adhesion molecule-1-dependent and -independent binding mechanisms. J Immunol 1991; 146: 592-598.
24. Matzinger P. The danger model: A renewed sense of self. Science 2002; 296: 301-305.
25. Steinman RM, Nussenzweig MC. Avoiding horror autotoxicus: The importance of dendritic cells in peripheral T cell tolerance. Proc Natl Acad Sci USA 2002; 99: 351-358.
26. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392: 245-252.
27. Wang J, Shaw JL, Mullen CA. Down-regulation of antihost alloreactivity after bone marrow transplant permits relapse of hematological malignancy. Cancer Res 2002; 62: 208-212.
28. Arber C, Passweg JR, Fluckiger U, Pless M, Gregor M, Tichelli A et al. C-reactive protein and fever in neutropenic patients. Scand J Infect Dis 2000; 32: 515-520.
29. Nash RA, Storb R. Graft-versus-host effect after allogeneic hematopoietic stem cell transplantation: GVHD and GVL. Curr Opin Immunol 1996; 8: 674-680.
30. Szalai AJ, McCrory MA, Cooper GS, Wu J, Kimberly RP. Association between baseline levels of C-reactive protein (CRP) and a dinucleotide repeat polymorphism in the intron of the CRP gene. Genes Immun 2002; 3: 14-19.
31. Zee RY, Ridker PM. Polymorphism in the human C-reactive protein (CRP) gene, plasma concentrations of CRP, and the risk of future arterial thrombosis. Atherosclerosis 2002; 162: 217-219.
32. Bidwell J, Keen L, Gallagher G, Kimberly R, Huizinga T, McDermott MF et al. Cytokine gene polymorphism in human disease: On-line databases, supplement 1. Genes Immun 2001; 2: 61-70.
33. Min CK, Lee WY, Min DJ, Lee DG, Kim YJ, Park YH et al. The kinetics of circulating cytokines including IL-6, TNF-alpha, IL-8 and IL-10 following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2001; 28: 935-940.